Fenglei Wu
Nanjing Medical University, China
Title: Effect of hENT1 polymorphism G-706C on clinical outcomes of gemcitabine-containing chemotherapy for Chinese non-small cell lung cancer patients
Biography
Biography: Fenglei Wu
Abstract
Both genotype and allele frequency of hENT1G-706C polymorphism differed significantly between responders and poor-responders. To be more specific, the response rate in the patients carrying GG genotype was substantially higher than that in the patients with GC or CC genotype. Using logistic regression analysis, we found that GC or CC genotype presented higher risk of being poor-responders compared with the GG genotype (OR=2.34, 95% CI: 1.14–4.80; P=0.02). The overall survival in patients with GG genotype were significantly higher than those with GC or CC genotype (19.0 vs.15.1 months, P<0.001). The hazard ratio for (GC+CC) genotype was 1.89 (95 % CI: 1.23–2.90, compared with GG carriers, P=0.004).